Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 12/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131840 | 0.95 | POLB (0.42) | POLBPDE4AQPCTAAK1PDE4D | |
| SCHEMBL3126037 | 0.87 | PDE4D (0.43) | PDE4AAAK1PDE4DPDE4BPDE4C | |
| SCHEMBL3132677 | 0.82 | PDE4B (0.41) | PDE4AAAK1PDE4DPDE4BPDE4C | |
| SCHEMBL3133564 | 0.81 | POLB (0.48) | POLBPDE4AQPCTPDE4DPDE4B | |
| SCHEMBL3120371 | 0.81 | AAK1 (0.41) | AAK1PDE4B | |
| SCHEMBL3121042 | 0.80 | BRD4 (0.50) | AAK1 | |
| SCHEMBL3131230 | 0.79 | KDM4E (0.40) | AAK1 | |
| SCHEMBL3133279 | 0.78 | POLB (0.51) | POLBPDE4AQPCTPDE4DPDE4B | |
| SCHEMBL3121303 | 0.78 | AAK1 (0.41) | AAK1 | |
| SCHEMBL3117586 | 0.78 | BRD4 (0.50) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | POLB 1798/4885PDE4A 1/4885QPCT 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.